key: cord-0051221-fh1ltgeq
authors: Yin, Yuyao; Zhao, Chunjiang; Li, Henan; Jin, Longyang; Wang, Qi; Wang, Ruobing; Zhang, Yawei; Zhang, Jiangang; Wang, Hui
title: Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China
date: 2020-10-07
journal: Eur J Clin Microbiol Infect Dis
DOI: 10.1007/s10096-020-04046-9
sha: bb4ae868b82ee5d52255a73ffb000f709043a430
doc_id: 51221
cord_uid: fh1ltgeq

Hospital-acquired pneumonia (HAP) is a significant nosocomial infection; data on the distribution and antimicrobial resistance profiles of HAP in China are limited. We included 2827 adult patients with HAP from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections network admitted in 15 Chinese teaching hospitals between 2007 and 2016. Clinical data and antimicrobial susceptibility of isolated pathogens were obtained from the medical records and central laboratory, respectively. Multivariable logistic regression was performed to determine the risk factors for mortality and multidrug resistance (MDR). A total of 386 (13.7%) patients died in the hospital, while 1181 (41.8%) developed ventilator-associated pneumonia (VAP). Active immunosuppressant therapy (OR 1.915 (95% CI 1.475–2.487)), solid tumor (OR 1.860 (95% CI 1.410–2.452)), coma (OR 1.783 (95% CI 1.364–2.333)), clinical pulmonary infection score ≥7 (OR 1.743 (95% CI 1.373–2.212)), intensive care unit stay (OR 1.652 (95% CI 1.292–2.111)), age ≥65 years (OR 1.621 (95% CI 1.282–2.049)), and tracheal cannula insertion (OR 1.613 (95% CI 1.169–2.224)) were independent risk factors for in-hospital mortality. Liver cirrhosis (OR 3.120 (95% CI 1.436–6.780)) and six other variables were independent predictors of MDR. Acinetobacter baumannii (25.6%), Pseudomonas aeruginosa (20.1%), Klebsiella pneumoniae (15.4%), and Staphylococcus aureus (12.6%) were the most common pathogens (MDR prevalence 64.9%). Isolates from VAP patients showed more A. baumannii and less K. pneumoniae and E. coli strains (p < 0.001, respectively) than those from patients without VAP. The proportion of methicillin-resistant S. aureus strains decreased; that of carbapenem-resistant A. baumannii and Enterobacterales strains increased. There had been changes in the antibiotic resistance profiles of HAP pathogens in China. Risk factors for mortality and MDR are important for the selection of antimicrobials for HAP in China. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10096-020-04046-9) contains supplementary material, which is available to authorized users.

Hospital-acquired pneumonia (HAP) is the second most frequent hospital-acquired infection and the main cause of mortality from nosocomial infections [1] . HAP and ventilatorassociated pneumonia (VAP) are significantly related to prolonged hospital stay and increased healthcare costs [2, 3] . The distribution and antimicrobial susceptibilities of causative pathogens isolated from patients with HAP differ in each region and individual situation [4] [5] [6] . Empiric antibiotic treatments should be selected based on the local data as recommended in the latest American Thoracic Society (ATS)/ Infectious Diseases Society of America (IDSA) guidelines published in 2016 [5] . However, there is limited literature on the distribution and antimicrobial resistance profiles of HAP in China.

The Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) is a nationwide surveillance program established in 2007 aimed at investigating the antibiotic resistance profiles of pathogens causing hospital-acquired infections in China. The results of this program will be used as a basis for developing and implementing Chinese guidelines. Here, we aimed to report the clinical and microbiological characteristics of adults with HAP from this 10-year prospective observational study in China, and provide more information on the risk factors for mortality and multidrug-resistant (MDR) infection.

The present study included patients with HAP who were aged ≥18 years from the CARES network and were admitted in 15 teaching hospitals between January 2007 and December 2016. All patients had radiographically confirmed pneumonia and appropriate clinical findings. Patients with other kind of infiltrate were excluded. HAP that occurred 48 h or more after hospital admission and VAP that occurred >48 h after endotracheal intubation were defined according to the ATS/IDSA guidelines [5] . Data were collected from each hospital's electronic health record system and included demographic characteristics, pre-existing medical conditions, clinical presentations, antimicrobial therapy administration, and outcomes. Duplicate cases or duplicate isolates from the same patient were excluded. The present study was approved by the Research Ethics Board at Peking University People's Hospital (Beijing, China).

HAP pathogens were isolated and identified in each participating center following the standard operating procedures. Then, all isolates were processed and antibiotic susceptibility testing were performed at the Clinical Microbiology Laboratory of Peking University People's Hospital. The agar dilution method and broth microdilution method (tigecycline and polymyxin B) were used to measure the susceptibilities of the bacterial strains, in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines [7] . The results were interpreted based on the latest CLSI breakpoints [8] . The tigecycline test was performed in accordance with the Food and Drug Administration standards. The tested antimicrobial agents included amikacin, ceftazidime, ceftazidime/clavulanic acid, cefotaxime, cefotaxime/clavulanic acid, cefepime, cefoxitin, chloramphenicol, clindamycin, erythromycin, levofloxacin, minocycline, moxifloxacin, polymyxin B, rifampicin, teicoplanin, trimethoprim-sulfamethoxazole, vancomycin (National Institute for Food and Drug Control of China, China), cefoperazone/sulbactam, linezolid, piperacillin/ tazobactam, tigecycline (Pfizer, Inc., USA), ceftriaxone (Hoffmann-La Roche Ltd., Switzerland), ciprofloxacin ( B a y e r A G , G e r m a n y ) , d a p t o m y c i n ( C u b i s t Pharmaceuticals, Inc., USA), imipenem (Merck & Co., Inc., USA), and meropenem (Sumitomo Dainippon Pharma, Japan). The reference isolates Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 2 9 2 1 3 , E s c h e r i c h i a c o l i A T C C 2 5 9 2 2 , a n d Pseudomonas aeruginosa ATCC 27853 were used as quality control isolates. The isolates resistant to at least three different antimicrobial classes were considered as MDR and all methicillin-resistant S. aureus (MRSA) isolates are defined as MDR [9, 10] . A patient isolated with multiple organisms was considered to have an MDR infection when one of the isolates was MDR. Isolates resistant to imipenem or meropenem were classified as carbapenem resistant.

Continuous variables were expressed as median (IQR) and compared using one-way ANOVA; categorical variables were expressed as frequency counts (%) and compared using the χ 2 test or Fisher's exact test. The threshold for statistical significance was p ≤0.05, and all tests were two tailed. A stepwise conditional logistic regression analysis was performed in survivor versus non-survivor and MDR versus non-MDR to determine the independent risk factors [11] . The variables about recent antibiotic exposure and bacteria species and resistance were excluded in the logistic regression analysis of survivor versus non-survivor and MDR versus non-MDR, respectively. A univariate logistic regression analysis was performed to estimate the ORs and corresponding 95% CIs. All variables with p values ≤0.05 were included in the multivariable model. A logistic regression was carried out using IBM SPSS Statistics version 20.0 (IBM, Armonk, NY).

During the 10-year study period, 2827 cases fulfilled our inclusion criteria, and their demographic, clinical, and microbiological characteristics are shown in Table 1 . More patients in general wards (62.2%) were diagnosed with HAP than in intensive care units (ICUs; 37.8%). VAP accounted for 40.7% isolates (766/1181 (64.9%)) were more frequent in patients with VAP than in those without VAP. The MDR rates among A. baumannii and S. aureus isolates were 74.6% and 70.9%. The MDR rates among P. aeruginosa, K. pneumoniae, and E. coli were 27.9%, 29.6%, and 44.5%, respectively. The MDR profiles of A. baumannii, K. pneumoniae, and P. aeruginosa are shown in Table A5 .

Among the isolates in patients with HAP, MRSA markedly decreased from 86.5% in 2007 to 66.1% in 2016 in our study (Fig. 1) . Meanwhile, marked changes were shown: the proportions of carbapenem-resistant A. baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) increased from 42.6% and 0.8% in 2007 to 79.2% and 11.6% in 2016, respectively. The carbapenem resistance rates in P. aeruginosa were relatively stable in the same period (36.6-44.8%). Meanwhile, significant differences were observed in the rates of MRSA, CRAB, CRE, carbapenem-resistant P. aeruginosa (CRPA), and MDR (p < 0.05, respectively).

Our univariate logistic regression analysis showed that 14 study variables were significantly related to in-hospital mortality ( Table 3 ). The final multivariate logistic regression models identified seven independent risk factors associated with in-hospital mortality using stepwise variable selection (Table 3) : active immunosuppressant therapy (OR 1.915 

The multivariate logistic regression model analysis showed that liver cirrhosis (OR 3.120 (95% CI 1.436-6.780)), infection that occurred in the ICU (OR 

This prospective observational multicenter study demonstrated clinical and microbiological characteristics of 2827 patients with HAP from 15 teaching hospitals during a 10-year period. In the present study, we demonstrated the updated distribution and antimicrobial susceptibility of the isolated pathogens and investigated the risk factors for the HAP-related mortality and harboring MDR pathogen. The local distribution and antibiotic resistance profile of pathogens causing HAP are significant for the selection of empiric antimicrobial therapy [12] . Moreover, the resistance profiles differed among the institutions. Similar to previous studies [6, 13] , gram-negative bacteria, especially nonfermentative bacteria, were the most frequent causative pathogens of HAP in the present study. A. baumannii was the most frequent pathogen and most of them is MDR. The distribution of pathogens causing HAP remained stable. Our results suggest that non-fermentative bacteria should be considered when selecting empiric antimicrobials in China. The trends of CRAB, CRPA, CRE, and MRSA from 2007 to 2016 reported in our study were consistent with the data from the China Antimicrobial Surveillance Network, which is a well-known Chinese national surveillance network for bacterial resistance [14] .

The all-cause mortality rate associated with HAP was 13.7% in the present study, which is lower than that reported in previous studies conducted in China. The HAP clinical survey results of 13 large Chinese teaching hospitals showed that the average all-cause mortality rate of HAP was 22.3%, of which that of VAP was 34.5% [13] . The all-cause mortality rate of VAP in the present study was 20.7%, which was also lower than that reported in a recent study conducted in China (45%) [6] . The difference in the in-hospital mortality reported in our study and the 28-day mortality reported in other studies may explain the lower mortality rates. However, a recent 3year prospective multicenter cohort study conducted in Japan and a recent retrospective study conducted in China showed HAP mortality rate (13.6% and 14.5%, respectively) similar with those reported in our study [15, 16] .

Older age, ICU, and tracheal cannula were associated with higher mortality due to HAP, which is consistent with the finding of previous studies [15] [16] [17] . Although the CPIS has shown a low diagnostic performance in recent studies [18, 19] , CPIS ≥7 was a risk factor for mortality due to HAP in our study. Patients receiving immunosuppressants, including the patients using active immunosuppressant and having solid tumors, had significantly higher mortality rate than those receiving non-immunosuppressant agents. These results are consistent with those of previous studies showing that HAP in transplant patients was common and was linked to increased mortality [20] . Unlike other previous studies, the mortality rates did not increase in patients with MDR pathogens [15, 16] .

The risk factors for MDR pathogens should be evaluated in order to determine the appropriate clinical empiric therapy for suspected VAP and HAP in accordance with the 2016 ATS/ IDSA guidelines [5] . The timely identification of MDR pathogens can improve the patient's clinical outcomes and prevent the necessary administration of superfluous antimicrobial agents that may result in adverse drug effects, Clostridium difficile infections, antibiotic resistance, and extra economic costs. The risk factors for MDR pathogens detected in our study were similar to those observed in previous studies and partially overlap, including the duration of ICU stay, prior antimicrobial therapy [21] , and chronic liver disease [15] . Previous studies also defined some important risk factors, including colonized with MDR [22] , age [15] , and chronic obstructive pulmonary disease [23] . Transferred from other hospitals was associated with MDR in our study. A possible explanation is that the patients transferred from other hospitals had a longer duration of hospitalization.

Our study has several limitations. First, our study was conducted in 15 tertiary care hospitals; hence, the results cannot be generalized to other smaller Chinese hospitals. In addition, the pathogens identified in the present study were obtained from sputa sample, accounting for 60%, which may not have been the cause of pneumonia. Third, the appropriateness of antimicrobial treatments was not evaluated in our study. Finally, as for other multicenter studies based mainly on electronic health records, some risk factors were not adequately reported as the reporting procedures were not fully assessed.

In conclusion, distribution of pathogens causing HAP in China remained stable, while their antibiotic resistance profiles gradually changed in the last decade, indicating that close monitoring of those pathogens is crucial for preventing further emergence of resistance, the development of treatment guidelines, and improving clinical therapy. The risk factors for HAP mortality and MDR pathogens will serve as a basis to appropriately manage high-risk populations in the future.

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilatorassociated pneumonia: guidelines for the management of hospitalacquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the

Economic impact of ventilator-associated pneumonia in a large matched cohort

Epidemiology and outcomes of ventilatorassociated pneumonia in a large US database

High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia

Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the

The current epidemiological landscape of ventilator-associated pneumonia in the intensive care unit: a multicenter prospective observational study in China

M07 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically

M100 Performance standards for antimicrobial susceptibility testing

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis

New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs

Analysis of pathogen spectrum and resistance of clinical common organisms causing bloodstream infections, hospital-acquired pneumonia and intra-abdominal infections from thirteen teaching hospitals in 2013

Current status and trends of antibacterial resistance in China

A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy

Factors influencing mortality in hospitalacquired pneumonia caused by Gram-negative bacteria in China

Clinical characteristics and prognostic risk factors of healthcare-associated pneumonia in a Korean tertiary teaching hospital

Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome

A comparison of APACHE II and CPIS scores for the prediction of 30-day mortality in patients with ventilator-associated pneumonia

Is hospital-acquired pneumonia different in transplant recipients?

Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes

Risk factors for hospitalized patients with resistant or multidrugresistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgments The authors would like to thank the participating investigators and institutions of the CARES network. The members from 16 Availability of data and materials The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Consent to participate Informed consent was not required because the medical records and patient information were anonymously reviewed and collected in this observational study. For the participating hospitals, administrative permissions to access the raw samples were granted by the Research Department of the hospital.Consent for publication Not applicable.

Authors' contributions H.W. conceived and designed the study. C.Z., H.L., L.J., Q.W., R.W., Y.Z., and J.Z. led the data collection and performed the susceptibility testing. Y.Y. analyzed the data and wrote the manuscript. H.W. critically reviewed and edited the manuscript. All coauthors have read, commented, and approved the final version of the article.Funding This study (part of the CARES program) was supported by a research grant from Pfizer Inc. The funders had no role in the study design, data collection and interpretation, or decision to submit this work for publication.

Competing interests The authors declare that they have no competing interests.Ethics approval and consent to participate This study was approved by the Research Ethic Board at Peking University People's Hospital.